Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NCT #
NCT05252390
Condition(s)
Breast Cancer, Colorectal Cancer, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Solid Tumor
Molecular Target(s)
BET
Drug Classification(s)
Small Molecule
Agents(s)
None
Phase(s)
I/II
Mechanism of Action
NUV-868 is a small molecule bromodomain 2 (BD2)-selective bromodomain and extra-terminal domain (BET) inhibitor. The BET family of proteins have critical biological functions and are found to be altered in many human cancers.
Purpose
- How much of the study drug can be given alone and in combination with Olaparib or Enzalutamide with an acceptable level of side effects
- The effects of the study drug alone and in combination with Olaparib or Enzalutamide (good and bad)
- How much of the study drug is absorbed into the blood and how fast it is removed
- If research tests can be used in the future to predict who will benefit from the study drug when given alone or in combination with Olaparib or Enzalutamide
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.